AAPS Journal

Top Research Topics at Aaps Journal?

The journal is mainly concerned with subjects like Pharmacology, Pharmacokinetics, Pharmacology toxicology, Drug and In vivo. The studies tackled, which mainly focus on Pharmacology, apply to Pharmacy as well. Pharmacokinetics research featured in it incorporates concerns from various other topics such as Monoclonal antibody and Dosing.

The In vivo study tackled is a key component of adjacent topics in the area of In vitro.

• Pharmacology (35.57%)
• Pharmacokinetics (19.78%)
• Pharmacology toxicology (14.06%)

What are the most cited papers published in the journal?

• Effects of protein aggregates: an immunologic perspective. (1104 citations)
• Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials (974 citations)
• Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models (822 citations)

Research areas of the most cited articles at Aaps Journal:

The journal articles investigate areas of study like Pharmacology, Pharmacokinetics, Drug, Pharmacology toxicology and Drug development. The published papers explore research in In vivo and overlapping concepts in In vitro to expand the discourse in Pharmacology. The published articles facilitate discussions on Pharmacology toxicology that incorporate concepts from other fields like Bioanalysis, Chromatography, Nanotechnology and Biochemical engineering.

What topics the last edition of the journal is best known for?

• Internal medicine
• Enzyme
• Gene

The previous edition focused in particular on these issues:

Aaps Journal aims to foster the development of research in Pharmacokinetics, Pharmacology, In vivo, Drug and Pharmacology toxicology. The journal focuses on Pharmacokinetics but the discussions also offer insight into other areas such as Physiology, Dosing and Renal function. The presented research on Pharmacology deals specifically with Immunogenicity but it also addresses topics in Ligand binding assay.

Chromatography, In vitro, Antigen and Cancer research are some topics wherein In vivo research discussed in Aaps Journal have an impact. The featured Drug studies mainly concentrate on Drug delivery but also cover areas of interest in Biomedical engineering. The research on Pharmacology toxicology featured in it combines topics in other fields like Pharmacy, Computational biology and Biodistribution.

The most cited articles from the last journal are:

• Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. (16 citations)
• Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. (13 citations)
• Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker. (8 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Aaps Journal (based on the number of publications) are:

• Mats O. Karlsson (39 papers) published 5 papers at the last edition, 3 more than at the previous edition,
• Boris Gorovits (26 papers) published 1 paper at the last edition, 5 less than at the previous edition,
• Marilyn E. Morris (25 papers) published 2 papers at the last edition the same number as at the previous edition,
• Lawrence X. Yu (23 papers) published 1 paper at the last edition,
• Robert Lionberger (22 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Aaps Journal (based on the number of publications) are:

• Pfizer (162 papers) published 7 papers at the last edition, 14 less than at the previous edition,
• Center for Drug Evaluation and Research (110 papers) published 12 papers at the last edition, 1 more than at the previous edition,
• Bristol-Myers Squibb (104 papers) published 5 papers at the last edition, 2 less than at the previous edition,
• Merck & Co. (96 papers) published 9 papers at the last edition, 5 less than at the previous edition,
• Food and Drug Administration (85 papers) published 1 paper at the last edition, 5 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 1.82% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 39.81% were posted by at least one author from the top 10 institutions publishing in the journal. Another 12.04% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 24.07% of all publications and 24.07% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.